Literature DB >> 10217653

Infective endocarditis in hypertrophic cardiomyopathy: prevalence, incidence, and indications for antibiotic prophylaxis.

P Spirito1, C Rapezzi, P Bellone, S Betocchi, C Autore, M R Conte, G P Bezante, P Bruzzi.   

Abstract

BACKGROUND: The literature on infective endocarditis in hypertrophic cardiomyopathy (HCM) is virtually confined to case reports. Consequently, the risk of endocarditis in HCM remains undefined. METHODS AND
RESULTS: We assessed the occurrence of endocarditis in 810 HCM patients evaluated between 1970 and 1997. Endocarditis was diagnosed in 10 patients, 2 of whom were excluded from analysis of prevalence and incidence because they were referred for acute endocarditis. At first evaluation, echocardiographic features consistent with prior endocarditis were identified in 3 of 808 patients, a prevalence of 3.7 per 1000 patients (95% CI, 0.8 to 11). Of 681 patients who were followed, 5 developed endocarditis, an incidence of 1.4 per 1000 person-years (95% CI, 0.5 to 3.2); outflow obstruction was present in each of these 5 patients and was associated with the risk of endocarditis (P=0.006). In the 224 obstructive patients, incidence of endocarditis was 3.8 per 1000 person-years (95% CI, 1.6 to 8.9) and probability of endocarditis 4. 3% at 10 years. Left atrial size was also associated with the risk of endocarditis (P=0.007). In patients with both obstruction and atrial dilatation (>/=50 mm), incidence of endocarditis increased to 9.2 per 1000 person-years (95% CI, 2.5 to 23.5). Analysis of all 10 patients with endocarditis identified outflow obstruction in each and atrial dilatation in 7.
CONCLUSIONS: Endocarditis in HCM is virtually confined to patients with outflow obstruction and is more common in those with both obstruction and atrial dilatation. These results indicate that antibiotic prophylaxis is required only in patients with obstructive HCM.

Entities:  

Mesh:

Year:  1999        PMID: 10217653     DOI: 10.1161/01.cir.99.16.2132

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  22 in total

Review 1.  Management of hypertrophic cardiomyopathy.

Authors:  Paolo Spirito; Camillo Autore
Journal:  BMJ       Date:  2006-05-27

2.  Gemella morbillorum endocarditis in hypertrophic cardiomyopathy: a rare organism causing a large vegetation and abscess in an uncommon setting.

Authors:  Vikram B Kolhari; V Vinoth Kumar; Navin Agrawal; Sadashivappa Surhonne Prakash
Journal:  BMJ Case Rep       Date:  2014-05-19

3.  Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy.

Authors:  P M Elliott; J R Gimeno; R Thaman; J Shah; D Ward; S Dickie; M T Tome Esteban; W J McKenna
Journal:  Heart       Date:  2005-10-10       Impact factor: 5.994

4.  Natural history of hypertrophic cardiomyopathy.

Authors:  P M Elliott
Journal:  Curr Cardiol Rep       Date:  2000-03       Impact factor: 2.931

Review 5.  The mitral valve in hypertrophic cardiomyopathy: old versus new concepts.

Authors:  Albert A Hagège; Patrick Bruneval; Robert A Levine; Michel Desnos; Hany Neamatalla; Daniel P Judge
Journal:  J Cardiovasc Transl Res       Date:  2011-09-10       Impact factor: 4.132

Review 6.  Mitral valve endocarditis in hypertrophic cardiomyopathy: case report and literature review.

Authors:  G Morgan-Hughes; J Motwani
Journal:  Heart       Date:  2002-06       Impact factor: 5.994

7.  Approach to Hypertrophic Cardiomyopathy.

Authors:  Camillo Autore; Paolo Spirito; Paolo Spirito
Journal:  Curr Treat Options Cardiovasc Med       Date:  2004-12

Review 8.  Management of hypertrophic cardiomyopathy in children.

Authors:  Hubert Seggewiss; Angelos Rigopoulos
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

9.  Subaortic-Right Atrial Fistula after Endocarditis in Hypertrophic Cardiomyopathy.

Authors:  Sung-Kien Sia; Yi-Liang Wu; Der-Jinn Wu; Ming-Cheng Lin; Kwo-Chang Ueng
Journal:  Acta Cardiol Sin       Date:  2013-07       Impact factor: 2.672

10.  Calcific embolization with infective endocarditis involving the posterior mitral leaflet in a patient with underlying hypertrophic obstructive cardiomyopathy.

Authors:  Navneet Lather; Kyle Niziolek; Peter Toth; David M Harris
Journal:  J Thromb Thrombolysis       Date:  2015-02       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.